Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 22, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 925,000 ordinary shares of 25 pence each.
- Purchase Price: 1,348.1062 pence per share.
- Treasury Shares Held: 224,189,678 shares (post-transaction).
- Shares in Issue: 5,765,303,344 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on November 22, 2006. This action was authorized by shareholders at the Annual General Meeting held on May 17, 2006. The purchased shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 925,000 share repurchase based on the disclosed price of 1,348.1062 pence.
- Confirm the updated total share count (5,765,303,344 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authorization.
- Note that this filing does not contain operational or financial performance data for the period.